Short Interest in BioNTech SE (NASDAQ:BNTX) Declines By 16.2%

BioNTech SE (NASDAQ:BNTX) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 2,020,000 shares, a decline of 16.2% from the October 15th total of 2,410,000 shares. Based on an average daily trading volume, of 997,700 shares, the short-interest ratio is currently 2.0 days.

Analyst Ratings Changes

A number of research analysts recently issued reports on BNTX shares. TD Cowen dropped their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. UBS Group raised their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and increased their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday. Finally, Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $137.54.

BioNTech Stock Down 3.7 %

BioNTech stock traded down $3.84 during midday trading on Friday, reaching $99.72. The stock had a trading volume of 3,377,161 shares, compared to its average volume of 865,257. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The firm’s 50-day moving average price is $113.54 and its 200 day moving average price is $97.24.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the firm earned $0.73 EPS. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, research analysts predict that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares during the last quarter. Covestor Ltd grew its holdings in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after acquiring an additional 223 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares in the last quarter. Finally, Capital International Sarl boosted its stake in BioNTech by 1.3% during the 1st quarter. Capital International Sarl now owns 24,058 shares of the company’s stock valued at $2,219,000 after purchasing an additional 310 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.